Peptides9 min read
Petrelintide and other amylin drugs: a useful comparison
Amylin medicines share a biological starting point, but differ in design, treatment partners and the clinical questions their trials answer.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Cagrilintide nausea: what tolerability tells us beyond efficacy
Cagrilintide nausea needs more context than an adverse-event percentage. Read the evidence on timing, discontinuation and the distinction from weight benefit.
Read article
Peptides9 min read
Do survodutide liver findings apply to everyone with fatty liver?
How diagnosis, fibrosis stage and trial eligibility determine which survodutide liver findings are relevant to an individual patient.
Read article
Peptides9 min read
GHK-Cu and copper nutrition: why the distinction matters
Copper is essential, but copper-binding chemistry does not make GHK-Cu a proven deficiency treatment or make dietary limits apply to injections.
Read article
Peptides8 min read
Why GHRP-2 hormone testing is not the same as a wellness protocol
A GHRP-2 stimulation test assesses hormone secretion. Learn what its validation studies show and why they do not establish an ongoing wellness treatment.
Read article
Peptides8 min read
Blood-sugar swings in diabetic cats: what exenatide research adds
Glucose averages can hide fluctuations. A secondary exenatide analysis explains the promise and limits of measuring variability in diabetic cats.
Read article
Peptides8 min read
Oxytocin safety: why a familiar hormone still needs careful study
Short-term tolerability findings are useful, but they don't establish that every oxytocin product, route or duration is harmless.
Read article
Peptides8 min read
Light tolerance in EPP: what extra time outdoors can mean
Light tolerance in EPP can mean symptom-free minutes, accumulated sunlight hours or greater freedom outdoors. Each outcome needs patient context.
Read article
Peptides9 min read
Does amylin therapy have to work through nausea?
Human meal studies show why appetite effects and nausea should be measured separately—and why that does not make newer amylin drugs symptom-free.
Read article
Peptides9 min read
Tesamorelin with integrase inhibitors: what the 2024 analysis adds
A small 2024 subgroup analysis found favorable tissue changes with tesamorelin in people taking integrase inhibitors. Its population and design define the limits.
Read article
Peptides8 min read
Amylin plus GLP-1: when two hormone pathways improve treatment
Human trials show when amylin and GLP-1 activity add weight benefit, why glucose results can differ and why zenagamtide is distinct from CagriSema.
Read article
Peptides9 min read
What Humanin needs before a clinical longevity claim
Humanin has intriguing aging biology, but genetics, biomarkers and animal results leave specific gaps before a clinical longevity claim.
Read article157–168 of 321 articles